{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T14:41:39Z","timestamp":1659364899992},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00106-016-0235-6","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T16:32:31Z","timestamp":1473265951000},"page":"723-730","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapie der rezidivierten und fernmetastasierten Kopf-Hals-Tumoren"],"prefix":"10.1007","volume":"64","author":[{"given":"L.","family":"Bu\u00dfmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.-J.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Knecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"key":"235_CR1","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2016.34.15_suppl.6041","volume":"34(suppl):abstr","author":"SR Ayyappan","year":"2016","unstructured":"Ayyappan SR, Savvides P, Prabhakar D et\u00a0al (2016) Correlation of hypomagnesemia from cetuximab with survival in metastatic squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 34(suppl):abstr:6041","journal-title":"J Clin Oncol"},{"key":"235_CR2","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1200\/JCO.2016.34.15_suppl.6030","volume":"34(suppl):abstr","author":"N Baste","year":"2016","unstructured":"Baste N, Brana I, Viros D et al (2016) Impact of molecular prescreening for genomically-guided trials in head and neck cancer (HNC). J Clin Oncol 34(suppl):abstr:6030","journal-title":"J Clin Oncol"},{"key":"235_CR3","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2016.34.15_suppl.6027","volume":"34(suppl):abstr","author":"AK Bhatia","year":"2016","unstructured":"Bhatia AK, Mehra R, Khan SA et\u00a0al (2016) Phase II trial of carboplatin\/paclitaxel and cetuximab, followed by carboplatin\/paclitaxel\/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 34(suppl):abstr:6027","journal-title":"J Clin Oncol"},{"key":"235_CR4","doi-asserted-by":"crossref","first-page":"TPS6104","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS6104","volume":"34(suppl):abstr","author":"KJ Harrington","year":"2016","unstructured":"Harrington KJ, Forster MD, Dillon M et al (2016) Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study. J Clin Oncol 34(suppl):abstr:TPS6104","journal-title":"J Clin Oncol"},{"key":"235_CR5","doi-asserted-by":"crossref","first-page":"TPS6102","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS6102","volume":"34(suppl):abstr","author":"B Keam","year":"2016","unstructured":"Keam B, Tahara M, Lin J\u2011C et al (2016) An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4\/6 inhibitor) plus cetuximab in patients with recurrent\/metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 34(suppl):abstr:TPS6102","journal-title":"J Clin Oncol"},{"key":"235_CR6","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.1200\/JCO.2016.34.15_suppl.6062","volume":"34(suppl):abstr","author":"JE Leeman","year":"2016","unstructured":"Leeman JE, Li J\u2011G, Venigalla P et al (2016) Natural history following recurrence after definitive locoregional treatment in 1000+ cases of locally advanced head and neck squamous cell carcinoma. J Clin Oncol 34(suppl):abstr:6062","journal-title":"J Clin Oncol"},{"key":"235_CR7","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.1200\/JCO.2016.34.15_suppl.6045","volume":"34(suppl):abstr","author":"LF Licitra","year":"2016","unstructured":"Licitra LF, Faivre SJ, Chol M et al (2016) BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients with head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 34(suppl):abstr:6045","journal-title":"J Clin Oncol"},{"key":"235_CR8","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1200\/JCO.2016.34.15_suppl.6067","volume":"34(suppl):abstr","author":"A Lopez-Pousa","year":"2016","unstructured":"Lopez-Pousa A, Sumarroca A, Quer M et al (2016) Risk of distant metastases in head and neck carcinoma patients and myeloperoxidase (MPO) expression. J Clin Oncol 34(suppl):abstr:6067","journal-title":"J Clin Oncol"},{"key":"235_CR9","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1200\/JCO.2016.34.15_suppl.6029","volume":"34(suppl):abstr","author":"R Mesia","year":"2016","unstructured":"Mesia R, Bossi P, Hansen AR et al (2016) Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced\/metastatic nasopharyngeal cancer (NPC). J Clin Oncol 34(suppl):abstr:6029","journal-title":"J Clin Oncol"},{"key":"235_CR10","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1200\/JCO.2016.34.15_suppl.6031","volume":"34(suppl):abstr","author":"A Prawira","year":"2016","unstructured":"Prawira A, Oosting S, Chen TW-W et al (2016) Systemic therapies for recurrent\/metastatic nasopharyngeal carcinoma (RM NPC). J Clin Oncol 34(suppl):abstr:6031","journal-title":"J Clin Oncol"},{"key":"235_CR11","doi-asserted-by":"crossref","first-page":"TPS6105","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS6105","volume":"34(suppl):abstr","author":"D Rischin","year":"2016","unstructured":"Rischin D, Boyer MJ, Brzezniak CE et\u00a0al (2016) A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS). J Clin Oncol 34(suppl):abstr:TPS6105","journal-title":"J Clin Oncol"},{"key":"235_CR12","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1200\/JCO.2016.34.15_suppl.6008","volume":"34(suppl):abstr","author":"D Soulieres","year":"2016","unstructured":"Soulieres D, Faivre SJ, Mesia R et al (2016) BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent\/metastatic head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 34(suppl):abstr:6008","journal-title":"J Clin Oncol"},{"key":"235_CR13","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1200\/JCO.2016.34.15_suppl.6026","volume":"34(suppl):abstr","author":"M Tahara","year":"2016","unstructured":"Tahara M, Kiyota N, Yokota T et al (2016) Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). J Clin Oncol 34(suppl):abstr:6026","journal-title":"J Clin Oncol"},{"key":"235_CR14","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1200\/JCO.2016.34.15_suppl.6034","volume":"34(suppl):abstr","author":"CS Tan","year":"2016","unstructured":"Tan CS, Wang TT, Lim C\u2011M et al (2016) Randomised study of 2 low doses of sunitinib to modulate tumor microvasculature prior to chemotherapy in nasopharyngeal carcinoma (NPC). J Clin Oncol 34(suppl):abstr:6034","journal-title":"J Clin Oncol"},{"key":"235_CR15","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116\u20131127","journal-title":"N Engl J Med"},{"key":"235_CR16","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1200\/JCO.2016.34.15_suppl.6046","volume":"34(suppl):abstr","author":"X Wan","year":"2016","unstructured":"Wan X, Fan X (2016) Molecular decision tree algorithms to predict individual recurrence pattern for locally advanced nasopharyngeal carcinoma. J Clin Oncol 34(suppl):abstr:6046","journal-title":"J Clin Oncol"},{"key":"235_CR17","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1200\/JCO.2016.34.15_suppl.6007","volume":"34(suppl):abstr","author":"L Zhang","year":"2016","unstructured":"Zhang L, Yu G, Jia J et al (2016) Gemcitabine plus cisplatin (GP) versus 5\u2011FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial. J Clin Oncol 34(suppl):abstr:6007","journal-title":"J Clin Oncol"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-016-0235-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-016-0235-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-016-0235-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T14:08:04Z","timestamp":1659362884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-016-0235-6"}},"subtitle":["Highlights des ASCO-Meetings 2016"],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["235"],"URL":"https:\/\/doi.org\/10.1007\/s00106-016-0235-6","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]},"assertion":[{"value":"7 September 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Bu\u00dfmann und C.-J.\u00a0Busch geben an, dass kein Interessenkonflikt besteht. R.\u00a0Knecht gibt folgende Interessenskonflikte an: Advisory Board BMS, AstraZeneca, Aventis und Merck Serono.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}